We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+9.12%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.4B
AUM Growth
-$236M
(-9%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-16.46%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
97
New
20
Increased
44
Reduced
26
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$85.4M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$45.1M |
| 3 |
Merck
MRK
|
+$36.1M |
| 4 |
Edwards Lifesciences
EW
|
+$21.1M |
| 5 |
CMRX
Chimerix, Inc.
CMRX
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$80.2M |
| 2 |
AGN
Allergan plc
AGN
|
+$63.6M |
| 3 |
Viatris
VTRS
|
+$58.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$54.9M |
| 5 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$48.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Universal Health Services
UHS
$9.43B
| $9.54M | 0.4% |
67,146
+1,207
| +2% | +$151K |
|
52
Perrigo
PRGO
$1.4B
| $4.95M | 0.21% |
26,780
-241,844
| -90% | -$46.1M |
|
53
Bausch Health
BHC
$1.65B
| $4.46M | 0.19% |
20,081
+11,980
| +148% | +$2.66M |
|
|
MNK
54
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $4.18M | 0.17% |
35,545
-307,825
| -90% | -$38M |
|
55
Ascendis Pharma A/S
ASND
$16.7B
| $4.17M | 0.17% |
235,560
-496,100
| -68% | -$8.68M |
|
|
MNTA
56
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $2.96M | 0.12% |
129,542
-1,454,468
| -92% | -$29M |
|
|
AKRX
57
DELISTED
Akorn Inc
AKRX
| $2.94M | 0.12% |
67,398
-399,270
| -86% | -$18.5M |
|
|
IPXL
58
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.34M | 0.1% |
50,915
+11,218
| +28% | +$532K |
|
|
EGRX
59
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $2.28M | 0.1% |
28,169
+6,046
| +27% | +$394K |
|
|
HZNP
60
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.28M | 0.09% |
65,501
+14,025
| +27% | +$428K |
|
61
Jazz Pharmaceuticals
JAZZ
$15.9B
| $2.1M | 0.09% |
11,948
+2,543
| +27% | +$457K |
|
62
McKesson
MCK
$98.5B
| $2.02M | 0.08% |
8,968
+1,973
| +28% | +$456K |
|
|
LCI
63
DELISTED
Lannett Company, Inc.
LCI
| $1.94M | 0.08% |
8,149
+1,740
| +27% | +$418K |
|
|
ENDP
64
DELISTED
Endo International plc
ENDP
| $1.89M | 0.08% |
23,771
+5,083
| +27% | +$439K |
|
65
Alkermes
ALKS
$8.82B
| $1.86M | 0.08% |
28,923
+6,153
| +27% | +$377K |
|
|
ASRT
66
DELISTED
Assertio
ASRT
| $1.5M | 0.06% |
1,169
+258
| +28% | +$354K |
|
67
Nektar Therapeutics
NKTR
$2.39B
| $1.25M | 0.05% |
6,657
+1,383
| +26% | +$238K |
|
68
Pacira BioSciences
PCRX
$1.02B
| $1.25M | 0.05% |
17,632
+3,693
| +26% | +$291K |
|
|
CYTO
69
DELISTED
Altamira Therapeutics Ltd
CYTO
| $1.11M | 0.05% |
3
| – | – |
|
|
ACHN
70
DELISTED
Achillion Pharmaceuticals
ACHN
| $872K | 0.04% |
98,400
-3,092,172
| -97% | -$29.2M |
|
|
CBM
71
DELISTED
Cambrex Corporation
CBM
| $648K | 0.03% |
14,744
+3,071
| +26% | +$127K |
|
72
Amphastar Pharmaceuticals
AMPH
$825M
| $640K | 0.03% |
36,400
-697,532
| -95% | -$10.9M |
|
|
CTLT
73
DELISTED
CATALENT, INC.
CTLT
| $526K | 0.02% |
17,922
+3,629
| +25% | +$109K |
|
74
Coherus Oncology
CHRS
$217M
| $462K | 0.02% |
15,974
+3,318
| +26% | +$83.9K |
|
75
Stryker
SYK
$127B
| $40K | ﹤0.01% |
+420
| New | +$39.8K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, Sectoral Asset Management held 97 positions worth $2.4B, down 9% from $2.63B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sectoral Asset Management withdrew a net $395M in Q2 2015, closing 6 positions and reducing 26 holdings. Its most notable exit was Keryx Biopharmaceuticals Inc, an estimated $48.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Regeneron Pharmaceuticals worth $89.2M.
- Sectoral Asset Management's largest Q2 2015 buy was Regeneron Pharmaceuticals: 174,900 shares worth $89.2M.
- Sectoral Asset Management added most to Alexion Pharmaceuticals in Q2 2015, an estimated $45.1M increase.
- Sectoral Asset Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $80.2M.
- Sectoral Asset Management fully exited Keryx Biopharmaceuticals Inc in Q2 2015, selling an estimated $48.7M.
- Sectoral Asset Management's ten largest holdings make up 49% of its $2.4B portfolio in Q2 2015.
- Sectoral Asset Management opened 20 new positions and closed 6 in Q2 2015.
- Sectoral Asset Management's portfolio value fell 9% quarter-over-quarter to $2.4B.
Based on Sectoral Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.